Search results
Novavax's New CEO Leads Vaccine Trial Success, and Big Layoffs Too
Motley Fool· 12 months agoNovavax (NASDAQ: NVAX) investors have been on edge ever since the company fell behind in the...
Novavax CEO eyes next batch of COVID-19 vaccines after CDC approval
Yahoo Finance via AOL· 2 years agoNovavax passed the finish line to gain authorization for its COVID-19 vaccine, and its first...
What’s in the Novavax Vaccine? Experts Break It All Down
Prevention via Yahoo News· 2 years agoThe Food and Drug Administration has authorized Novavax’s COVID-19 vaccine for use in the U.S....
Novavax Stock May Soar 379%, According to Wall Street. Is the Stock a Buy Right Now?
Motley Fool via Yahoo Finance· 3 months agoNovavax (NASDAQ: NVAX) soared more than 2,700% early in the pandemic as investors bet on its ability...
FDA advisory panel to consider approving fourth COVID-19 vaccine, this one from Maryland's Novavax
USA TODAY via Yahoo News· 2 years agoA federal vaccine advisory committee meets Tuesday to decide whether adult Americans could soon get...
A more traditional coronavirus shot is on the way. Some people can't wait.
Washington Post via Yahoo News· 2 years agoMore than a year after people began rolling up their sleeves for cutting-edge coronavirus shots, a...
1 Reason to Buy Novavax in 2023 and 2 Reasons to Sell
Motley Fool· 1 year agoNovavax (NASDAQ: NVAX) has offered investors just such a ride over the past few years. Initial gains...
A ‘breadth of protection’: Novavax’s newly approved COVID vaccine arms the U.S. with a new weapon...
Fortune via Yahoo Finance· 2 years agoThe U.S. Food and Drug Administration (FDA) on Wednesday approved the COVID-19 vaccine from American...
Novavax Won a Nod From FDA Advisors. Now What?
Motley Fool· 2 years agoIt's the moment Novavax (NASDAQ: NVAX) and its investors have been waiting for. A U.S. Food and Drug Administration (FDA) advisory panel voted for the...
Is It Too Late to Buy Novavax Stock?
Motley Fool· 2 years agoBiotech company Novavax (NASDAQ: NVAX) has had a terrible year on the stock market, with its shares down by 86% year to date. The company does still face...
